MEDFORD, N.Y. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care ("POC") diagnostics company focused on infectious diseases, today announced the receipt of U.S. Food and Drug Administration ( FDA ) Emergency Use Authorization (EUA) for its DPP®
MEDFORD, N.Y. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced plans to participate in two upcoming investor conferences. Chembio’s Chief Executive Officer, John Sperzel , will be
MEDFORD, N.Y. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the third quarter ended September 30, 2018 . Recent Accomplishments & Highlights Achieved
MEDFORD, N.Y. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today the pricing of its previously announced underwritten registered public offering of 2,370,435 shares of its
MEDFORD, N.Y. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ: CEMI) (“Chembio”), a provider of point-of-care diagnostic tests for infectious diseases, announced today that it has commenced an underwritten registered public offering of its common stock.
MEDFORD, N.Y. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter 2018 after the close of trading on Thursday, November
MEDFORD, N.Y. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) today announced that it has determined not to proceed with the proposed public offering of $25 million of its common stock previously announced on October 22, 2018 .
MEDFORD, N.Y. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio” or the “Company”), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has commenced an underwritten public offering of $25 million of its common
Signs Definitive Agreement to Acquire opTricon GmbH MEDFORD, N.Y. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) (“Chembio” or the “Company”), a leading point-of-care diagnostics company focused on infectious diseases, today announced preliminary financial results for
MEDFORD, N.Y. , Oct. 16, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has received a $10.5 million commitment from Bio-Manguinhos to purchase test components and intermediate
Print Page